Key result
Heart transplantation yields an uneventful primary course in two patients with end-stage doxorubicin-induced cardiomyopathy.
Why the study?
Does heart transplantation provide a viable therapeutic option for pediatric patients with end-stage doxorubicin-induced cardiomyopathy?
Case Report (n=2)
Does heart transplantation provide a viable therapeutic option for pediatric patients with end-stage doxorubicin-induced cardiomyopathy?
Heart transplantation is a viable and potentially life-saving therapeutic option for patients with end-stage doxorubicin-induced cardiomyopathy who have been in complete remission from malignancy for over 5 years.
No takes yet. Share an insight, caveat, or question.
May support transplantation in select end-stage cases after remission; leaves open confirmation in larger pediatric cohorts.
Lindberg et al. (1987) conducted a case report in End-stage doxorubicin-induced cardiomyopathy (n=2). Heart transplantation was evaluated on Primary clinical course. Heart transplantation was successfully performed with an uneventful primary course in two patients with end-stage doxorubicin-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: